WINDTREE THERAPEUTICS INC /DE/
WINT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for WINT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · WINT
Windtree Therapeutics Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies, currently holding a novel aPKCi inhibitor asset with both topical and oral formulations, but faces significant financial challenges with minimal cash and a history of operating losses.
Key risk: Liquidity and capital risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2025.
Tracking 3 pipeline candidates · 1 clinical trial for WINDTREE THERAPEUTICS INC /DE/.
Windtree Therapeutics Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies, currently holding a novel aPKCi inhibitor asset with both topical and oral formulations, but faces significant financial challenges with minimal cash and a history of operating losses.
- Windtree Therapeutics is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions [sec_mda · as of 2025-11-19].
- The company's lead asset is a novel, potential high-potency, specific aPKCi inhibitor with possible use in oncology and rare malignant diseases, available in topical and oral formulations [sec_mda · as of 2025-11-19].
- As of September 30, 2025, the company had cash & equivalents of $0.2M and a net loss of $28.1M for the nine months ended September 30, 2025 [sec].
- Windtree has an accumulated deficit of $846.6 million as of December 31, 2024 [sec_mda · as of 2025-04-15].
- The company is actively seeking partnerships, licensing arrangements, and other strategic collaborations to support development and commercialization [sec_mda · as of 2025-11-19].
What works
- The aPKCi inhibitor asset is described as novel and potential high-potency, with broad oncology applications and two formulations (topical and oral) [sec_mda · as of 2025-11-19].
- The company is actively engaged in discussions with potential partners for licensing, drug product development, and marketing collaborations, which could provide non-dilutive funding [sec_mda · as of 2025-11-19].
- Windtree is pursuing multiple funding avenues, including public/private securities offerings and government grants, to support its pipeline [sec_mda · as of 2025-11-19].
What to weigh
- The company has incurred net losses since inception, with a net loss of $28.1 million for the nine months ended September 30, 2025 [sec_mda · as of 2025-11-19].
- As of September 30, 2025, cash & equivalents were only $0.2M, indicating very limited liquidity [sec].
- The company has a material weakness in internal control over financial reporting, which could lead to loss of investor confidence and restrict access to capital markets [sec · filed 2025-10-24].
- There is no assurance that the company will be able to secure additional capital on acceptable terms, and failure could force it to limit or cease operations [sec_mda · as of 2025-08-19].
From the filings
Quoted directly from source documents.
The company holds a novel aPKCi inhibitor asset with topical and oral formulations.
“The Transferred Assets include a novel, potential high-potency, specific, aPKCi inhibitor with possible broad use in oncology as well as certain rare malignant diseases. The asset platform includes two formulations (topical and oral) of an aPKCi inhibitor.”
SEC MD&A · November 19, 2025
The company has a material weakness in internal control over financial reporting.
“Failure to remedy any material weakness in our internal control over financial reporting, or to maintain effective control systems, could also restrict our future access to the capital markets.”
SEC filings · October 24, 2025
The company has an accumulated deficit of $846.6 million as of December 31, 2024.
“As of December 31, 2024 , we had an accumulated deficit of $846.6 million.”
SEC MD&A · April 15, 2025
The company is actively seeking partnerships and collaborations.
“a key element of our business strategy is to seek and establish strategic collaborations, licensing arrangements, and other partnerships that can support the advancement and commercialization of our product candidates.”
SEC MD&A · November 19, 2025
Risks & what to watch (4)›
Key risks
- Liquidity and capital risk — Cash & equivalents of only $0.2M as of 2025-09-30 [sec]; the company may not secure sufficient additional capital, potentially forcing it to limit or cease operations [sec_mda · as of 2025-08-19].
- Material weakness in internal controls — A material weakness in internal control over financial reporting could lead to loss of investor confidence and restrict access to capital markets [sec · filed 2025-10-24].
- History of operating losses — The company has incurred net losses since inception, with a net loss of $28.1M for the nine months ended 2025-09-30 [sec_mda · as of 2025-11-19].
- Dependence on partnerships — The company's strategy relies on establishing partnerships, but there is no assurance that such partnerships will be secured on acceptable terms [sec_mda · as of 2025-11-19].
What to watch
- Ability to secure additional capital through public/private offerings, partnerships, or grants [sec_mda · as of 2025-11-19].
- Progress in IND-enabling activities and determination of the clinical development plan for the aPKCi inhibitor [sec_mda · as of 2025-11-19].
- Resolution of the material weakness in internal control over financial reporting [sec · filed 2025-10-24].
- Any updates on strategic collaborations or licensing agreements [sec_mda · as of 2025-11-19].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run WINDTREE THERAPEUTICS INC /DE/ through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available WINDTREE THERAPEUTICS INC /DE/ facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
1.1 months
OCF -$6M · Net income -$28M
Lead: Phase 1/Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Jun 2025Institutional holders
5
Total value held
$8K
| Holder | Shares | Value |
|---|---|---|
| jane street group, llc | 14,599 | $8K |
| bank of america corp /de/ | 103 | $53 |
| sbi securities co., ltd. | 24 | $12 |
| ubs group ag | 22 | $11 |
| concourse financial group securities, inc. | 0 | $0 |
Short Interest
as of May 22, 2026- % of float
- 6.3%
- Days to cover
- 0.1
- Shares short
- 1,790,483
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
WINT short interestFrequently asked questions
What is the AI investment thesis for WINDTREE THERAPEUTICS INC /DE/?
Windtree Therapeutics Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies, currently holding a novel aPKCi inhibitor asset with both topical and oral formulations, but faces significant financial challenges with minimal cash and a history of operating losses.
What is WINDTREE THERAPEUTICS INC /DE/'s lead drug candidate?
WINDTREE THERAPEUTICS INC /DE/'s most advanced tracked candidate is apkci inhibitor (Preclinical) for Solid tumors.
Who is the CEO of WINDTREE THERAPEUTICS INC /DE/?
Mr. Jed A. Latkin is the chief executive officer of WINDTREE THERAPEUTICS INC /DE/ (WINT).
Where is WINDTREE THERAPEUTICS INC /DE/ headquartered?
WINDTREE THERAPEUTICS INC /DE/ (WINT) is headquartered in Warrington, PA, United States.
What therapeutic areas does WINDTREE THERAPEUTICS INC /DE/ focus on?
WINDTREE THERAPEUTICS INC /DE/ develops therapies across Oncology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.